Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm

Trial Profile

Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Azacitidine (Primary) ; Ruxolitinib (Primary)
  • Indications Myelodysplastic syndromes; Myelofibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Mar 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2021.
    • 14 Mar 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.
    • 06 Jun 2017 Results (n=35) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top